12/09/14, Research and Development Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River Blindness more
12/01/14, Research and Development Bayer to Present Latest Data on Its Hematology and Oncology Portfolio Three-year results from the Phase III SPINART study for octocog alfa (Kogenate® FS) in patients with hemophilia A / New data on damoctocog alfa pegol (BAY 94-9027) for the treatment of hemophilia A / Presentations on copanlisib and sorafenib in patients with different hematological cancers more
|Research expenses 2013||EUR 1,654 million|
|In percent of division sales 2013
|Employees in Research & Development||7,800
(as of Dec 31, 2013)
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.